Analysts are intrested in these 5 stocks: ( ($ETSY) ), ( ($CLS) ), ( ($BIIB) ), ( ($SRPT) ) and ( ($M) ). Here is a breakdown ...

Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Squawk Box' to discuss the troubles facing Sarepta and its ...

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular ...

To suggest Sarepta Therapeutics may not survive its gene therapy crisis is a sobering claim to make, STAT's Adam Feuerstein ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $106.75, a high estimate of $202.00, and a low estimate of $75.00.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...

One thing we could say about the analysts on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts ...

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ:SRPT), expressing a variety of opinions spanning from bullish to bearish.The table below ...